Edition:
United States

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

37.91USD
16 Feb 2018
Change (% chg)

$-0.66 (-1.71%)
Prev Close
$38.57
Open
$38.67
Day's High
$38.67
Day's Low
$37.50
Volume
156,581
Avg. Vol
308,026
52-wk High
$49.15
52-wk Low
$24.68

Chart for

About

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosi... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $1,690.48
Shares Outstanding(Mil.): 44.59
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018

* RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE

Dec 15 2017

BRIEF-Point72 Asset Management Reports 5.1 Percent Passive Stake In Radius Health

* POINT72 ASSET MANAGEMENT, L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN RADIUS HEALTH INC AS OF NOVEMBER 24, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2iXLIQS) Further company coverage:

Nov 27 2017

BRIEF-Radius Health reports Q3 loss per share $1.31

* Radius Health Inc reports third quarter 2017 financial and operating results and provides business update

Nov 02 2017

BRIEF-Radius Health receives FDA fast track designation for elacestrant

* Radius health receives fda fast track designation for elacestrant (rad1901)

Oct 18 2017

BRIEF-Radius Health initiates Phase 1 clinical trial of RAD140 for treatment of hormone receptor positive breast cancer

* Radius Health initiates Phase 1 clinical trial of RAD140 for the treatment of hormone receptor positive breast cancer

Sep 29 2017

Earnings vs. Estimates